search
Back to results

Combination Treatment Study in Subjects With Tophaceous Gout With Lesinurad and Febuxostat (CRYSTAL)

Primary Purpose

Tophaceous Gout

Status
Completed
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Lesinurad
Lesinurad
Placebo
Febuxostat
Sponsored by
Ardea Biosciences, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Tophaceous Gout

Eligibility Criteria

18 Years - 85 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Subject is able to understand the study procedures, the risks involved and willing to provide written informed consent before the first study related activity.
  • Subject is willing to adhere to the visit/protocol schedules.
  • Subject meets the diagnosis of gout as per the American Rheumatism Association
  • Criteria for the Classification of Acute Arthritis of Primary Gout.
  • Subject meets one of the following criteria:
  • Subjects who are not currently taking an approved ULT must have an sUA value of ≥ 8 mg/dL (476 µmol/L).
  • Subjects entering the study on a medically appropriate dose of febuxostat or allopurinol must have an sUA value of ≥ 6.0 mg/dL (357 µmol/L).
  • Subject must be able to take gout flare prophylaxis with colchicine or non-steroidal anti-inflammatory drug (NSAID) (including Cox-2 selective NSAID) ± PPI.
  • Subject with at least 1 measurable tophus on the hands/wrists and/or feet/ankles ≥ 5 mm and ≤ 20 mm in the longest diameter.
  • Body mass index (BMI) < 45 kg/m2

Exclusion Criteria:

  • Subject with known hypersensitivity or allergy to febuxostat.
  • Subject who is taking any approved urate-lowering medication other than allopurinol or febuxostat that is indicated for the treatment of gout within 8 weeks of the Screening Visit.
  • Subject who previously received pegloticase.
  • Subject who consumes more than 14 drinks of alcohol per week (eg, 1 drink = 5 oz [150 mL] of wine, 12 oz [360 mL] of beer, or 1.5 oz [45 mL] of hard liquor).
  • Subject with a history or suspicion of drug abuse within the past 5 years.
  • Subject with a history of myositis/myopathy or rhabdomyolysis.
  • Subject that requires or may require systemic immunosuppressive or immunomodulatory treatment.
  • Subject with known or suspected human immunodeficiency virus (HIV) infection.
  • Subject with a positive test for active hepatitis B or hepatitis C infection.
  • Subject with a history of malignancy within the previous 5 years with the exception of non-melanoma skin cancer that has been treated with no evidence of recurrence, treated cervical dysplasia or treated in situ Grade 1 cervical cancer.
  • Subject within the last 12 months with: unstable angina, New York Heart Association thrombosis; or subjects currently receiving anticoagulants.
  • Subject with uncontrolled hypertension.
  • Subject with an estimated creatinine clearance < 30 mL/min.
  • Subjects with a creatine kinase > 2.5 x ULN at any time during the Screening Period.
  • Subject with active peptic ulcer disease requiring treatment.
  • Subject with a history of xanthinuria, active liver disease, or hepatic dysfunction.
  • Subject receiving chronic treatment with more than 325 mg of salicylates per day.
  • Subject taking valpromide, progabide, or valproic acid.
  • Subject who has received an investigational therapy within 8 weeks or 5 half-lives (whichever is longer) prior to the Screening Visit.
  • Subject with any other medical or psychological condition, which in the opinion of the Investigator and/or Medical Monitor, might create undue risk to the subject or interfere with the subject's ability to comply with the protocol requirements, or to complete the study.

Sites / Locations

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Placebo Comparator

Arm Label

lesinurad 400 mg + febuxostat 80 mg

lesinurad 200 mg + febuxostat 80 mg

placebo + febuxostat 80 mg

Arm Description

Outcomes

Primary Outcome Measures

Subjects With a Serum Urate (sUA) Level That is < 5.0 mg/dL by Month 6
Proportion of subjects with an sUA level that is < 5.0 mg/dL by Month 6

Secondary Outcome Measures

Complete Resolution of at Least One Target Tophus
Proportion of subjects who experience complete resolution of at least 1 target tophus by Month 12
Complete or Partial Response of at Least One Tophus
Proportion of subjects with a best tophus response on at least 1 target tophus of complete (disappearance of at least 1 target tophus) or partial (≥ 50% decrease in the area of at least 1 target tophus) resolution by Month 12
Quality of Life
Proportion of subjects with an improvement from Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) of at least 0.25 at Month 12. The HAQ-DI assesses a patient's level of functional ability with items scores ranging from 0-3 with 0 being the least disability.

Full Information

First Posted
January 12, 2012
Last Updated
April 20, 2016
Sponsor
Ardea Biosciences, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT01510769
Brief Title
Combination Treatment Study in Subjects With Tophaceous Gout With Lesinurad and Febuxostat
Acronym
CRYSTAL
Official Title
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled, Combination Study to Evaluate the Efficacy and Safety of Lesinurad and Febuxostat Compared to Febuxostat Alone at Lowering Serum Uric Acid and Resolving Tophi in Subjects With Tophaceous Gout
Study Type
Interventional

2. Study Status

Record Verification Date
April 2016
Overall Recruitment Status
Completed
Study Start Date
January 2012 (undefined)
Primary Completion Date
June 2014 (Actual)
Study Completion Date
June 2014 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Ardea Biosciences, Inc.

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This study will compare the serum uric acid lowering effects, clinical benefits, and safety of lesinurad in combination with febuxostat to febuxostat alone in patients with tophaceaous gout.
Detailed Description
Febuxostat is an XO (Xanthine Oxidase) Inhibitor approved Urate Lowering Therapy (ULT) for patients with gout. Although febuxostat has been demonstrated to be superior to allopurinol in lowering serum urate (sUA) to < 6mg/dL in 3 randomized, controlled clinical trials, proportions of subjects experiencing a reduction in tophus area and gout flares were not significantly different compared to allopurinol. Although this study will allow subjects who are naïve to ULT to enroll, it is anticipated that the majority of subjects will currently be taking or have previously experienced XO Inhibitor therapy. This trial will enroll a population of subjects with high uric acid body burden, as all must demonstrate the presence of tophi.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Tophaceous Gout

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
330 (Actual)

8. Arms, Groups, and Interventions

Arm Title
lesinurad 400 mg + febuxostat 80 mg
Arm Type
Experimental
Arm Title
lesinurad 200 mg + febuxostat 80 mg
Arm Type
Experimental
Arm Title
placebo + febuxostat 80 mg
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
Lesinurad
Intervention Description
Tablets, 400 mg once daily (QD)
Intervention Type
Drug
Intervention Name(s)
Lesinurad
Intervention Description
Tablets, 200 mg QD
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Tablets, Placebo QD
Intervention Type
Drug
Intervention Name(s)
Febuxostat
Intervention Description
80 mg
Primary Outcome Measure Information:
Title
Subjects With a Serum Urate (sUA) Level That is < 5.0 mg/dL by Month 6
Description
Proportion of subjects with an sUA level that is < 5.0 mg/dL by Month 6
Time Frame
6 months, analysis after all subjects complete 12 months
Secondary Outcome Measure Information:
Title
Complete Resolution of at Least One Target Tophus
Description
Proportion of subjects who experience complete resolution of at least 1 target tophus by Month 12
Time Frame
12 Months
Title
Complete or Partial Response of at Least One Tophus
Description
Proportion of subjects with a best tophus response on at least 1 target tophus of complete (disappearance of at least 1 target tophus) or partial (≥ 50% decrease in the area of at least 1 target tophus) resolution by Month 12
Time Frame
12 Months
Title
Quality of Life
Description
Proportion of subjects with an improvement from Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) of at least 0.25 at Month 12. The HAQ-DI assesses a patient's level of functional ability with items scores ranging from 0-3 with 0 being the least disability.
Time Frame
12 Months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Subject is able to understand the study procedures, the risks involved and willing to provide written informed consent before the first study related activity. Subject is willing to adhere to the visit/protocol schedules. Subject meets the diagnosis of gout as per the American Rheumatism Association Criteria for the Classification of Acute Arthritis of Primary Gout. Subject meets one of the following criteria: Subjects who are not currently taking an approved ULT must have an sUA value of ≥ 8 mg/dL (476 µmol/L). Subjects entering the study on a medically appropriate dose of febuxostat or allopurinol must have an sUA value of ≥ 6.0 mg/dL (357 µmol/L). Subject must be able to take gout flare prophylaxis with colchicine or non-steroidal anti-inflammatory drug (NSAID) (including Cox-2 selective NSAID) ± PPI. Subject with at least 1 measurable tophus on the hands/wrists and/or feet/ankles ≥ 5 mm and ≤ 20 mm in the longest diameter. Body mass index (BMI) < 45 kg/m2 Exclusion Criteria: Subject with known hypersensitivity or allergy to febuxostat. Subject who is taking any approved urate-lowering medication other than allopurinol or febuxostat that is indicated for the treatment of gout within 8 weeks of the Screening Visit. Subject who previously received pegloticase. Subject who consumes more than 14 drinks of alcohol per week (eg, 1 drink = 5 oz [150 mL] of wine, 12 oz [360 mL] of beer, or 1.5 oz [45 mL] of hard liquor). Subject with a history or suspicion of drug abuse within the past 5 years. Subject with a history of myositis/myopathy or rhabdomyolysis. Subject that requires or may require systemic immunosuppressive or immunomodulatory treatment. Subject with known or suspected human immunodeficiency virus (HIV) infection. Subject with a positive test for active hepatitis B or hepatitis C infection. Subject with a history of malignancy within the previous 5 years with the exception of non-melanoma skin cancer that has been treated with no evidence of recurrence, treated cervical dysplasia or treated in situ Grade 1 cervical cancer. Subject within the last 12 months with: unstable angina, New York Heart Association thrombosis; or subjects currently receiving anticoagulants. Subject with uncontrolled hypertension. Subject with an estimated creatinine clearance < 30 mL/min. Subjects with a creatine kinase > 2.5 x ULN at any time during the Screening Period. Subject with active peptic ulcer disease requiring treatment. Subject with a history of xanthinuria, active liver disease, or hepatic dysfunction. Subject receiving chronic treatment with more than 325 mg of salicylates per day. Subject taking valpromide, progabide, or valproic acid. Subject who has received an investigational therapy within 8 weeks or 5 half-lives (whichever is longer) prior to the Screening Visit. Subject with any other medical or psychological condition, which in the opinion of the Investigator and/or Medical Monitor, might create undue risk to the subject or interfere with the subject's ability to comply with the protocol requirements, or to complete the study.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Chris Storgard, MD
Organizational Affiliation
Ardea Biosciences, Inc.
Official's Role
Study Director
Facility Information:
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35211
Country
United States
City
Goodyear
State/Province
Arizona
ZIP/Postal Code
85395
Country
United States
City
Peoria
State/Province
Arizona
ZIP/Postal Code
85381
Country
United States
City
Pheonix
State/Province
Arizona
ZIP/Postal Code
85023
Country
United States
City
Tucson
State/Province
Arizona
ZIP/Postal Code
85724
Country
United States
City
Little Rock
State/Province
Arkansas
ZIP/Postal Code
72204
Country
United States
City
Little Rock
State/Province
Arkansas
ZIP/Postal Code
72223
Country
United States
City
Glendale
State/Province
California
ZIP/Postal Code
91204
Country
United States
City
Huntington Beach
State/Province
California
ZIP/Postal Code
92646
Country
United States
City
Irvine
State/Province
California
ZIP/Postal Code
92618
Country
United States
City
La Jolla
State/Province
California
ZIP/Postal Code
92037
Country
United States
City
Los Angeles
State/Province
California
ZIP/Postal Code
90048
Country
United States
City
Rancho Cucamonga
State/Province
California
ZIP/Postal Code
91730
Country
United States
City
San Diego
State/Province
California
ZIP/Postal Code
92108
Country
United States
City
Denver
State/Province
Colorado
ZIP/Postal Code
80220
Country
United States
City
Denver
State/Province
Colorado
ZIP/Postal Code
80230
Country
United States
City
Englewood
State/Province
Colorado
ZIP/Postal Code
80113
Country
United States
City
Trumball
State/Province
Connecticut
ZIP/Postal Code
06611
Country
United States
City
Washington
State/Province
District of Columbia
ZIP/Postal Code
20422
Country
United States
City
Boynton Beach
State/Province
Florida
ZIP/Postal Code
33472
Country
United States
City
Brooksville
State/Province
Florida
ZIP/Postal Code
34601
Country
United States
City
East Brandenton
State/Province
Florida
ZIP/Postal Code
34208
Country
United States
City
Fleming Island
State/Province
Florida
ZIP/Postal Code
32003
Country
United States
City
Miami
State/Province
Florida
ZIP/Postal Code
33135
Country
United States
City
Napels
State/Province
Florida
ZIP/Postal Code
34102
Country
United States
City
Pembroke Pines
State/Province
Florida
ZIP/Postal Code
33027
Country
United States
City
Pembroke Pines
State/Province
Florida
ZIP/Postal Code
33029
Country
United States
City
Port Orange
State/Province
Florida
ZIP/Postal Code
32127
Country
United States
City
Tampa
State/Province
Florida
ZIP/Postal Code
33606
Country
United States
City
Tampa
State/Province
Florida
ZIP/Postal Code
33607
Country
United States
City
Tampa
State/Province
Florida
ZIP/Postal Code
33614
Country
United States
City
Vero Beach
State/Province
Florida
ZIP/Postal Code
32960
Country
United States
City
Winter Haven
State/Province
Florida
ZIP/Postal Code
33880
Country
United States
City
Conyers
State/Province
Georgia
ZIP/Postal Code
30013
Country
United States
City
Johns Creek
State/Province
Georgia
ZIP/Postal Code
30097
Country
United States
City
Newman
State/Province
Georgia
ZIP/Postal Code
30265
Country
United States
City
Savannah
State/Province
Georgia
ZIP/Postal Code
31406
Country
United States
City
Honolulu
State/Province
Hawaii
ZIP/Postal Code
96814
Country
United States
City
Meridian
State/Province
Idaho
ZIP/Postal Code
83642
Country
United States
City
Meridian
State/Province
Idaho
ZIP/Postal Code
83646
Country
United States
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60624
Country
United States
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60637
Country
United States
City
Gurnee
State/Province
Illinois
ZIP/Postal Code
60031
Country
United States
City
Springfield
State/Province
Illinois
ZIP/Postal Code
62704
Country
United States
City
Springfield
State/Province
Illinois
ZIP/Postal Code
62711
Country
United States
City
Elizabethtown
State/Province
Kentucky
ZIP/Postal Code
42701
Country
United States
City
Lexington
State/Province
Kentucky
ZIP/Postal Code
40504
Country
United States
City
Frederick
State/Province
Maryland
ZIP/Postal Code
21702
Country
United States
City
Kalamazoo
State/Province
Michigan
ZIP/Postal Code
49009
Country
United States
City
Southfield
State/Province
Michigan
ZIP/Postal Code
48034
Country
United States
City
Jackson
State/Province
Mississippi
ZIP/Postal Code
39202
Country
United States
City
Olive Branch
State/Province
Mississippi
ZIP/Postal Code
38654
Country
United States
City
Jefferson City
State/Province
Missouri
ZIP/Postal Code
65109
Country
United States
City
Saint Louis
State/Province
Missouri
ZIP/Postal Code
63117
Country
United States
City
Missoula
State/Province
Montana
ZIP/Postal Code
59808
Country
United States
City
Mineola
State/Province
New York
ZIP/Postal Code
11501
Country
United States
City
New York
State/Province
New York
ZIP/Postal Code
10016
Country
United States
City
Calabash
State/Province
North Carolina
ZIP/Postal Code
28467
Country
United States
City
Durham
State/Province
North Carolina
ZIP/Postal Code
27710
Country
United States
City
Greenville
State/Province
North Carolina
ZIP/Postal Code
27834
Country
United States
City
Wilmington
State/Province
North Carolina
ZIP/Postal Code
28401
Country
United States
City
Winston-Salem
State/Province
North Carolina
ZIP/Postal Code
27103
Country
United States
City
Fargo
State/Province
North Dakota
ZIP/Postal Code
58103
Country
United States
City
Columbus
State/Province
Ohio
ZIP/Postal Code
43203
Country
United States
City
Middleburg
State/Province
Ohio
ZIP/Postal Code
44130
Country
United States
City
Wadsworth
State/Province
Ohio
ZIP/Postal Code
44281
Country
United States
City
Oklahoma City
State/Province
Oklahoma
ZIP/Postal Code
73103
Country
United States
City
Oklahoma City
State/Province
Oklahoma
ZIP/Postal Code
73112
Country
United States
City
Belle Vernon
State/Province
Pennsylvania
ZIP/Postal Code
15012
Country
United States
City
Clairton
State/Province
Pennsylvania
ZIP/Postal Code
15025
Country
United States
City
Duncansville
State/Province
Pennsylvania
ZIP/Postal Code
16635
Country
United States
City
Jenkintown
State/Province
Pennsylvania
ZIP/Postal Code
19046
Country
United States
City
Lansdale
State/Province
Pennsylvania
ZIP/Postal Code
19446
Country
United States
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15206
Country
United States
City
Scottdale
State/Province
Pennsylvania
ZIP/Postal Code
15683
Country
United States
City
Sellersville
State/Province
Pennsylvania
ZIP/Postal Code
18960
Country
United States
City
Columbia
State/Province
South Carolina
ZIP/Postal Code
29204
Country
United States
City
Greenville
State/Province
South Carolina
ZIP/Postal Code
29615
Country
United States
City
Mount Pleasant
State/Province
South Carolina
ZIP/Postal Code
29464
Country
United States
City
Spartanburg
State/Province
South Carolina
ZIP/Postal Code
29303
Country
United States
City
Jackson
State/Province
Tennessee
ZIP/Postal Code
38305
Country
United States
City
Memphis
State/Province
Tennessee
ZIP/Postal Code
38119
Country
United States
City
Austin
State/Province
Texas
ZIP/Postal Code
78705
Country
United States
City
Austin
State/Province
Texas
ZIP/Postal Code
78758
Country
United States
City
Corpus Christi
State/Province
Texas
ZIP/Postal Code
78413
Country
United States
City
Dallas
State/Province
Texas
ZIP/Postal Code
75218
Country
United States
City
Houston
State/Province
Texas
ZIP/Postal Code
77004
Country
United States
City
Houston
State/Province
Texas
ZIP/Postal Code
77074
Country
United States
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78229
Country
United States
City
Sugar Land
State/Province
Texas
ZIP/Postal Code
77479
Country
United States
City
Victoria
State/Province
Texas
ZIP/Postal Code
77901
Country
United States
City
Waco
State/Province
Texas
ZIP/Postal Code
76708
Country
United States
City
Chesapeake
State/Province
Virginia
ZIP/Postal Code
23320
Country
United States
City
Danville
State/Province
Virginia
ZIP/Postal Code
24541
Country
United States
City
Richmond
State/Province
Virginia
ZIP/Postal Code
23235
Country
United States
City
Suffolk
State/Province
Virginia
ZIP/Postal Code
23435
Country
United States
City
Virginia Beach
State/Province
Virginia
ZIP/Postal Code
23462
Country
United States
City
Seattle
State/Province
Washington
ZIP/Postal Code
98104
Country
United States
City
Morgantown
State/Province
West Virginia
ZIP/Postal Code
26505
Country
United States
City
Camperdown
State/Province
New South Wales
ZIP/Postal Code
2050
Country
Australia
City
Woodville South
State/Province
South Australia
ZIP/Postal Code
5011
Country
Australia
City
Hobart
State/Province
Tasmania
ZIP/Postal Code
7000
Country
Australia
City
Shenton Park
State/Province
Western Australia
ZIP/Postal Code
6008
Country
Australia
City
Kelowna
State/Province
British Columbia
ZIP/Postal Code
V1Y 3G8
Country
Canada
City
Victoria
State/Province
British Columbia
ZIP/Postal Code
V8V 3N7
Country
Canada
City
Halifax
State/Province
Nova Scotia
ZIP/Postal Code
B3K 2M5
Country
Canada
City
London
State/Province
Ontario
ZIP/Postal Code
N6A 5R8
Country
Canada
City
Mississauga
State/Province
Ontario
ZIP/Postal Code
L5M 2V8
Country
Canada
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M9W 4L6
Country
Canada
City
Quebec
ZIP/Postal Code
G1V 3M7
Country
Canada
City
Grafton
State/Province
Auckland
ZIP/Postal Code
1010
Country
New Zealand
City
Tauranga
State/Province
Bay of Plenty
ZIP/Postal Code
3143
Country
New Zealand
City
Hamilton
ZIP/Postal Code
3240
Country
New Zealand
City
Kutno
State/Province
Lodz Province
ZIP/Postal Code
99-300
Country
Poland
City
Biatystok
ZIP/Postal Code
15-430
Country
Poland
City
Elblag
ZIP/Postal Code
82-300
Country
Poland
City
Katowice
ZIP/Postal Code
40-954
Country
Poland
City
Konskie
ZIP/Postal Code
26-200
Country
Poland
City
Krakow
ZIP/Postal Code
30-510
Country
Poland
City
Krakow
ZIP/Postal Code
31-501
Country
Poland
City
Poznan
ZIP/Postal Code
60-539
Country
Poland
City
Poznan
ZIP/Postal Code
60-773
Country
Poland
City
Lausanne
State/Province
Vlaud
ZIP/Postal Code
1011
Country
Switzerland
City
Fribourg
ZIP/Postal Code
1708
Country
Switzerland

12. IPD Sharing Statement

Citations:
PubMed Identifier
35835008
Citation
Topless R, Noorbaloochi S, Merriman TR, Singh JA. Change in serum urate level with urate-lowering therapy initiation associates in the immediate term with patient-reported outcomes in people with gout. Semin Arthritis Rheum. 2022 Oct;56:152057. doi: 10.1016/j.semarthrit.2022.152057. Epub 2022 Jun 29.
Results Reference
derived
PubMed Identifier
30616614
Citation
Dalbeth N, Jones G, Terkeltaub R, Khanna D, Fung M, Baumgartner S, Perez-Ruiz F. Efficacy and safety during extended treatment of lesinurad in combination with febuxostat in patients with tophaceous gout: CRYSTAL extension study. Arthritis Res Ther. 2019 Jan 7;21(1):8. doi: 10.1186/s13075-018-1788-4.
Results Reference
derived
PubMed Identifier
28597604
Citation
Dalbeth N, Jones G, Terkeltaub R, Khanna D, Kopicko J, Bhakta N, Adler S, Fung M, Storgard C, Baumgartner S, Perez-Ruiz F. Lesinurad, a Selective Uric Acid Reabsorption Inhibitor, in Combination With Febuxostat in Patients With Tophaceous Gout: Findings of a Phase III Clinical Trial. Arthritis Rheumatol. 2017 Sep;69(9):1903-1913. doi: 10.1002/art.40159. Epub 2017 Aug 4.
Results Reference
derived
Links:
URL
http://www.gouttrial.com
Description
Related Info

Learn more about this trial

Combination Treatment Study in Subjects With Tophaceous Gout With Lesinurad and Febuxostat

We'll reach out to this number within 24 hrs